Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Lyophilized IMVAMUNE® (1x10^8 TCID50) Versus Liquid IMVAMUNE® (1x10^8 TCID50) Administered Subcutaneously and a Lower Dose Liquid IMVAMUNE® (2x10^7 TCID50) Administered Intradermally

ClinicalTrials.gov ID: NCT00914732

Public ClinicalTrials.gov record NCT00914732. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jul 23, 2026, 5:13 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Comparison of the Safety and Immunogenicity of Lyophilized IMVAMUNE® (1x10^8 TCID50) Versus Liquid Formulation IMVAMUNE® (1x10^8 TCID50) Administered by the Subcutaneous Route and a Lower Dose Liquid Formulation IMVAMUNE® (2x10^7 TCID50) Administered by the Intradermal Route in Healthy Vaccinia-Naïve Individuals

Study identification

NCT ID
NCT00914732
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Enrollment
523 participants

Conditions and interventions

Conditions

Interventions

  • MVA Smallpox Vaccine Biological

Biological

Eligibility (public fields only)

Age range
18 Years to 38 Years
Sex
All
Healthy volunteers
Accepts healthy volunteers

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jan 31, 2010
Primary completion
Mar 31, 2011
Completion
Mar 31, 2011
Last update posted
Feb 2, 2021

2010 – 2011

United States locations

U.S. sites
8
U.S. states
7
U.S. cities
7
Facility City State ZIP Site status
Emory Vaccine Center - The Hope Clinic Decatur Georgia 30030-1705
University of Iowa - Vaccine Research & Education Unit Iowa City Iowa 52242-2600
University of Maryland School of Medicine - Center for Vaccine Development - Baltimore Baltimore Maryland 21201-1509
Saint Louis University - Center for Vaccine Development St Louis Missouri 63104-1015
Vanderbilt University Hospital - Pediatric Clinical Research Nashville Tennessee 37232-0004
Baylor College of Medicine - Molecular Virology and Microbiology Houston Texas 77030-3411
Group Health Research Institute - Seattle Seattle Washington 98101-1466
The University of Washington - Virology Research Clinic Seattle Washington 98104-2433

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00914732, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Feb 2, 2021 · Synced Jul 23, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00914732 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →